Medical devices with long term non-thrombogenic coatings

Details Medical devices with long term non-thrombogenic coatings Medical devices with long term non-thrombogenic coatings

1996-06-13

2000-09-19

Yu, Mickey

Prosthesis (i.e., artificial body members), parts thereof, or ai

Arterial prosthesis

Drug delivery

623 118, 623 146, 424424, 427 221, 427 224, A61F 206

Patent

active

061205362

ABSTRACT:
A coating and method for implantable open lattice metallic stent prostheses are disclosed. The coating includes a relatively thin layer of biostable elastomeric material containing an amount of biologically active material, particularly heparin, dispersed in the coating in combination with a non-thrombogenic surface. In one embodiment, the surface is provided with sites of high electronegativity species by coating with fluorosilicone which aid in controlling elution, particularly the initial release rate, and reduced thrombogenic activity. Other non-thrombogenic outer layers for heparin such as covalently bound polyethylene glycol (PEG) are also disclosed.

REFERENCES:
patent: 3932627 (1976-01-01), Margraf
patent: 4292965 (1981-10-01), Nash et al.
patent: 4613665 (1986-09-01), Larm
patent: 4655771 (1987-04-01), Wallsten
patent: 4872867 (1989-10-01), Joh
patent: 4886062 (1989-12-01), Wiktor
patent: 4916193 (1990-04-01), Tang et al.
patent: 4954126 (1990-09-01), Wallsten
patent: 4994071 (1991-02-01), McGregor
patent: 5053048 (1991-10-01), Pinchuk
patent: 5061275 (1991-10-01), Wallsten et al.
patent: 5092877 (1992-03-01), Pinchuk
patent: 5163952 (1992-11-01), Froix
patent: 5180366 (1993-01-01), Woods
patent: 5182317 (1993-01-01), Winters et al.
patent: 5185408 (1993-02-01), Tang et al.
patent: 5226913 (1993-07-01), Pinchuk
patent: 5258020 (1993-11-01), Froix
patent: 5262451 (1993-11-01), Winters et al.
patent: 5292802 (1994-03-01), Rhee et al.
patent: 5304121 (1994-04-01), Sahatjian
patent: 5308889 (1994-05-01), Rhee et al.
patent: 5338770 (1994-08-01), Winters et al.
patent: 5342348 (1994-08-01), Kaplan
patent: 5356433 (1994-10-01), Rowland et al.
patent: 5380299 (1995-01-01), Fearnot et al.
patent: 5415619 (1995-05-01), Lee et al.
patent: 5419760 (1995-05-01), Narciso, Jr.
patent: 5429618 (1995-07-01), Keogh
patent: 5447724 (1995-09-01), Helmus et al.
patent: 5449382 (1995-09-01), Dayton
patent: 5464650 (1995-11-01), Berg et al.
patent: 5500013 (1996-03-01), Buscemi et al.
patent: 5545208 (1996-08-01), Wolff et al.
patent: 5551954 (1996-09-01), Buscemi et al.
patent: 5578075 (1996-11-01), Dayton
patent: 5605696 (1997-02-01), Eury et al.
patent: 5624411 (1997-04-01), Tuch
patent: 5637113 (1997-06-01), Tartaglia et al.
Mansoor Amiji and Kinam Park, "Surface Modification of Polymeric Biomaterials with Poly(Ethylene Oxide), Albumin, and Heparin for Reduced Thrombogenicity", Purdue University, School of Pharmacy, West Lafayette, IN, 47907.
Bergstrom, Reduction of fibrinogen adsorption on PEG-coated polystyrene surfaces, 1992, pp. 779-790, Baxter Healthcare Corp. Duraflo Biocompatible Treatment.
Michael N. Helmus, "Medical Device Design--A Systems Approach: Central Venous Catheters", (1990).
Polysciences Inc., TDMAC-Heparin Coatings, Nov. 1988, Data Sheet #172.
Barbucci, et al., Coating of Commercially available materials with a new heparinizable material, 1991, pp. 1259-1274.
Michael N. Helmus, Grant Application-Ionic-Hydrophilic Density: Platelet/Monocyte Adherence 12/81, 12/84, pp. 13, 14, 26-31.
Dennis E. Chenoweth, Complement Activation in Extracorporeal Circuits, pp. 306-329.
Jeffrey A. Hubbell, Ph.D., Jul.-Sep. 1993 Pharmacologic Modification of Materials, 1215-1275.
Glenn P. Gravlee, MD, Heparin-Coated Cardiopulmonary Bypass Circuits, Journal of Cardiothoracic and Vascular Anesthesia, vol. 8, No. 2, Apr. 1994, pp. 213-222.
K. Isihara, H. Hanyuda, and N. Nakabayashi, Synthesis of phospholipid polymers having a urethane bond . . . , Biomaterials, 1995, pp. 873-879.
J. Sanchez, G. Elgue, J. Riesenfeld and P. Olsson, Control of Contact activation on end-point immobilized heparin, The role of antithrombin and the specific antithrombin-binding sequence, 1995, pp. 655-661, Journal of Biomedical Materials Research.
Cardiology Conference European Society of Cardiology Conference Clinica, Sep. 4, 1995, pp. 24-26.
Baxter Healthcare Corp. Duraflo Biocompatible Treatment.
Ludwig k. von Segesser, MD., "Heparin-Bonded Surfaces in Extracorporeal Membrane Oxygenation for Cardiac Support", The Society of Thoracic Surgeons, (1996).
Li-Chien Hsu, "Principles of Heparin-Coating Techniques", Perfusion 6: 209-219 (1991).
J.M. Toomasian et al., "Evaluation of Duraflo II Heparin Coating in Prolonged Extracorporeal Membrane Oxygenation", ASAIO Trans 34: 410-14 (1988).
S.D. Tong et al., "Non-Thrombogenic Hemofiltration System for Acute Renal Failure Treatment", ASAIO Trans. 38: M702-M706 (1992).

Affiliated with

Also associated with

Rating

Medical devices with long term non-thrombogenic coatings does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Medical devices with long term non-thrombogenic coatings, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Medical devices with long term non-thrombogenic coatings will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1067934